CRDF Cardiff Oncology Inc
Price (delayed)
$2.56
Market cap
$119.17M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.91
Enterprise value
$95.51M
Cardiff Oncology is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need. Its goal is to
Highlights
Cardiff Oncology's revenue has soared by 61% YoY and by 9% from the previous quarter
The gross profit has soared by 61% YoY and by 9% QoQ
The quick ratio has plunged by 51% YoY and by 15% from the previous quarter
The equity has declined by 39% year-on-year and by 14% since the previous quarter
Key stats
What are the main financial stats of CRDF
Market
Valuations
Earnings
Shares outstanding
46.55M
Market cap
$119.17M
Enterprise value
$95.51M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.19
Price to sales (P/S)
172.56
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
143.62
Revenue
$665,000
EBIT
-$40.86M
EBITDA
-$40.44M
Free cash flow
-$32.47M
Per share
Balance sheet
Liquidity
EPS
-$0.91
Free cash flow per share
-$0.72
Book value per share
$1.17
Revenue per share
$0.01
TBVPS
$1.47
Total assets
$66.05M
Total liabilities
$13.66M
Debt
$1.84M
Equity
$52.39M
Working capital
$49.72M
Debt to equity
0.04
Current ratio
4.97
Quick ratio
4.85
Net debt/EBITDA
0.59
Margins
Efficiency
Dividend
EBITDA margin
-6,081.2%
Gross margin
100%
Net margin
-6,143.9%
Operating margin
-6,711.3%
Return on assets
-52.7%
Return on equity
-62.7%
Return on invested capital
-84.4%
Return on capital employed
-76.3%
Return on sales
-6,143.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CRDF stock price
How has the Cardiff Oncology stock price performed over time
Intraday
10.82%
1 week
15.84%
1 month
13.27%
1 year
44.63%
YTD
72.97%
QTD
15.32%
Financial performance
How have Cardiff Oncology's revenue and profit performed over time
Revenue
$665,000
Gross profit
$665,000
Operating income
-$44.63M
Net income
-$40.86M
Gross margin
100%
Net margin
-6,143.9%
Cardiff Oncology's revenue has soared by 61% YoY and by 9% from the previous quarter
The gross profit has soared by 61% YoY and by 9% QoQ
Cardiff Oncology's net margin has increased by 36% YoY and by 7% QoQ
The operating margin rose by 35% year-on-year and by 8% since the previous quarter
Growth
What is Cardiff Oncology's growth rate over time
Valuation
What is Cardiff Oncology stock price valuation
P/E
N/A
P/B
2.19
P/S
172.56
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
143.62
The equity has declined by 39% year-on-year and by 14% since the previous quarter
The stock's price to book (P/B) is 6% less than its 5-year quarterly average of 2.1 but 3.7% more than its last 4 quarters average of 1.9
Cardiff Oncology's revenue has soared by 61% YoY and by 9% from the previous quarter
The P/S is 58% less than the 5-year quarterly average of 371.3 and 23% less than the last 4 quarters average of 202.8
Efficiency
How efficient is Cardiff Oncology business performance
The company's return on invested capital has shrunk by 87% YoY and by 23% QoQ
Cardiff Oncology's return on equity has shrunk by 59% YoY and by 15% QoQ
CRDF's return on assets is down by 48% year-on-year and by 12% since the previous quarter
Cardiff Oncology's return on sales has increased by 36% YoY and by 7% QoQ
Dividends
What is CRDF's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CRDF.
Financial health
How did Cardiff Oncology financials performed over time
The quick ratio has plunged by 51% YoY and by 15% from the previous quarter
The company's current ratio has shrunk by 51% YoY and by 16% QoQ
Cardiff Oncology's debt is 96% lower than its equity
The equity has declined by 39% year-on-year and by 14% since the previous quarter
The debt to equity has grown by 33% from the previous quarter and by 33% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.